Landscapes / Targets
PD-1
97 drugs act on PD-1, in 747 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs97
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PD-1 antibody |
Merck & Co. · Public MRK |
Approved | 20 Nov 2026soonPhase 3 trial completes | ||
| Next date | 20 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Melanoma and 250 more | ||||
| Open drug page | |||||
PD-1 antibody |
Approved | 23 Nov 2026soonPhase 2 trial completes | |||
| Next date | 23 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Neoplasms, Neoplasms, Endometrial and 23 more | ||||
| Open drug page | |||||
Programmed death ligand-1 blocker |
Approved | 24 Nov 2026soonPhase 3 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 24 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, Locally Advanced or Metastatic Urothelial Carcinoma | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Roche · Public ROG.SW |
Approved | 30 Nov 2026soonPhase 3 trial completes | ||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 30 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Cancer and 34 more | ||||
| Open drug page | |||||
PD-1/CTLA-4 bispecific antibody |
Akeso · Public 9926.HK |
Approved in China | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma and 23 more | ||||
| Open drug page | |||||
PD-1 antibody |
Approved | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Urothelial Carcinoma and 27 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Akeso +1 · Public 9926.HK · SMMT |
Approved in China | 1 Dec 2026soonPhase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 1 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Advanced Solid Tumors and 95 more | ||||
| Open drug page | |||||
— |
Approved | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Advanced Hepatocellular Carcinoma (HCC) | ||||
| Open drug page | |||||
— |
Approved in China | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Persistent, Recurrent, or Metastatic Cervical Cancer, Solid Tumor | ||||
| Open drug page | |||||
Monoclonal antibody |
Akeso · Public 9926.HK |
Approved | Dec 2026Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer Stage IIIB/IV and 3 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Approved | 1 Jan 2027Phase 1 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 1 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
PD-1 antibody |
Regeneron · Public REGN |
Approved | 15 Jan 2027Phase 3 trial completes | ||
| Next date | 15 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Melanoma, Fallopian Tube Cancer and 35 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Bristol Myers Squibb · Public BMY |
Approved | 5 Feb 2027Phase 2 trial completes | ||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 5 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, Advanced Solid Tumors and 31 more | ||||
| Open drug page | |||||
PD-1 antibody |
Henlius · Public 2696.HK |
Approved in China | 10 Feb 2027Phase 2 trial completes | ||
| Next date | 10 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, SCLC, Extensive Stage and 12 more | ||||
| Open drug page | |||||
PD-1 antibody |
CSPC · Public 1093.HK |
Approved in China | Apr 2027Phase 1/2 trial completes | ||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma and 7 more | ||||
| Open drug page | |||||
PD-1 antibody |
Innovent · Public 1801.HK |
Approved in China | 30 Jun 2027Phase 1/2 trial completes | ||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma and 12 more | ||||
| Open drug page | |||||
— |
Approved in China | Jun 2027Phase 1/2 trial completes | |||
| Next date | Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Carcinoma, Non-Small-Cell Lung and 8 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Approved | Sep 2027Phase 2 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma and 4 more | ||||
| Open drug page | |||||
— |
Junshi Biosciences · Public 1877.HK |
Approved | 31 Dec 2027Phase 2 trial completes | ||
| Next date | 31 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Malignant Solid Tumors, Triple-negative Breast Cancer | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved in China | Dec 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Recurrent or Metastatic Nasopharyngeal Carcinoma, Hepatocellular Carcinoma and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 92 of 97 drugs. The other 5 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026